Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

Evolocumab binds PCSK9, increasing low‐density lipoprotein cholesterol (LDL‐C) receptors and lowering LDL‐C. Target‐mediated evolocumab elimination is attributable to PCSK9 binding. As circulating PCSK9 and LDL‐C levels are primarily regulated by the liver, we compared evolocumab pharmacokinetics, p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Pharmacol
Hlavní autoři: Gibbs, John P., Slatter, J. Greg, Egbuna, Ogo, Geller, Michelle, Hamilton, Lisa, Dias, Clapton S., Xu, Ren Y., Johnson, Jessica, Wasserman, Scott M., Emery, Maurice G.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Special Populations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363371/
https://ncbi.nlm.nih.gov/pubmed/27667740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.832
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky